Inulin and calcimimetic combination further suppresses bone turnover and improves bone health in CKD rats

Secondary hyperparathyroidism (SHPT) is a significant complication of chronic kidney disease (CKD), leading to severe skeletal fragility and increased fracture risk. While existing parathyroid hormone (PTH)-lowering therapies, such as calcimimetics, effectively reduce circulating PTH levels, patients often still experience high rates of fractures. This suggests that PTH reduction alone is insufficient to fully restore bone health. There's a critical need for complementary strategies that address the multifaceted bone pathology in CKD beyond just hormonal control, potentially by targeting the gut-bone axis.

Researchers investigated the efficacy of a gut-targeted intervention in a rat model of chronic kidney disease. The study specifically examined the effects of combining inulin, a prebiotic fiber, with a calcimimetic, a standard PTH-lowering agent. The primary objective was to determine if this dual approach could offer superior benefits to bone health compared to calcimimetic therapy alone. The team assessed key indicators of bone health, including markers of bone turnover, detailed cortical bone architecture, and the mechanical properties of the bone tissue.

The combination of inulin and a calcimimetic demonstrated significant improvements in skeletal health beyond what was achieved with calcimimetic therapy alone. > The dual intervention further suppressed elevated bone turnover, a hallmark of SHPT that contributes to bone fragility. Specifically, the combined treatment led to improved cortical bone architecture, indicating enhanced structural integrity and organization of the bone. These architectural improvements were functionally significant, as the study also found enhanced mechanical properties of the bone, suggesting increased strength and resilience against fracture. These findings highlight a synergistic effect between gut-targeted prebiotics and conventional PTH-lowering drugs.